Which has better earnings and valuation, PYPD or QNTM?

PolyPid is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.48 N/A Quantum Biopharma N/A N/A -$26.17M -$5.49 N/A

Is PYPD or QNTM more profitable?

PolyPid's return on equity of -311.08% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Quantum Biopharma N/A -582.23% -184.20%

Does the media prefer PYPD or QNTM?

In the previous week, PolyPid had 7 more articles in the media than Quantum Biopharma. MarketBeat recorded 8 mentions for PolyPid and 1 mentions for Quantum Biopharma. PolyPid's average media sentiment score of 0.33 beat Quantum Biopharma's score of 0.00 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NTRB or QNTM?

Quantum Biopharma has a consensus target price of $8.00, indicating a potential upside of 132.56%. Given Quantum Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Quantum Biopharma is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to NTRB or QNTM?

In the previous week, Nutriband had 4 more articles in the media than Quantum Biopharma. MarketBeat recorded 5 mentions for Nutriband and 1 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.00 beat Nutriband's score of -0.10 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nutriband 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MIST or QNTM more profitable?

Milestone Pharmaceuticals' return on equity of -288.33% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -288.33% -58.27% Quantum Biopharma N/A -582.23% -184.20%

Do analysts rate ICCC or QNTM?

Quantum Biopharma has a consensus target price of $8.00, indicating a potential upside of 132.56%. Given Quantum Biopharma's higher possible upside, analysts clearly believe Quantum Biopharma is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, QNTM or CGTX?

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum Biopharma N/A N/A -$26.17M -$5.49 N/A Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A

Is QNTM or CGTX more profitable?

Cognition Therapeutics' return on equity of -50.17% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -582.23% -184.20% Cognition Therapeutics N/A -50.17% -40.22%

Does the media favor QNTM or CGTX?

In the previous week, Cognition Therapeutics had 2 more articles in the media than Quantum Biopharma. MarketBeat recorded 3 mentions for Cognition Therapeutics and 1 mentions for Quantum Biopharma. Cognition Therapeutics' average media sentiment score of 0.66 beat Quantum Biopharma's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Quantum Biopharma (QNTM) Competitors

$3.27 -0.17 (-4.94%)

Closing price 04:00 PM Eastern

Extended Trading

$3.41 +0.14 (+4.28%)

As of 07:56 PM Eastern

Compare

QNTM vs. PYPD, NTRB, MIST, ICCC, and CGTX

Should you buy Quantum Biopharma stock or one of its competitors? Quantum Biopharma's main competitors and comparable companies include PolyPid (PYPD), Nutriband (NTRB), Milestone Pharmaceuticals (MIST), ImmuCell (ICCC), and Cognition Therapeutics (CGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Quantum Biopharma compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

PolyPid currently has a consensus price target of $11.33, indicating a potential upside of 118.37%. Quantum Biopharma has a consensus price target of $8.00, indicating a potential upside of 132.56%. Given Quantum Biopharma's higher possible upside, analysts plainly believe Quantum Biopharma is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PolyPid is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

In the previous week, PolyPid had 7 more articles in the media than Quantum Biopharma. MarketBeat recorded 8 mentions for PolyPid and 1 mentions for Quantum Biopharma. PolyPid's average media sentiment score of 0.33 beat Quantum Biopharma's score of 0.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PolyPid's return on equity of -311.08% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Quantum Biopharma	N/A	-582.23%	-184.20%

PolyPid has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

Summary

PolyPid beats Quantum Biopharma on 10 of the 13 factors compared between the two stocks.

How does Quantum Biopharma compare to Nutriband?

Nutriband (NASDAQ:NTRB) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Quantum Biopharma has a consensus target price of $8.00, indicating a potential upside of 132.56%. Given Quantum Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Quantum Biopharma is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nutriband has higher revenue and earnings than Quantum Biopharma. Nutriband is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	43.39	-$8.23M	-$0.53	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

In the previous week, Nutriband had 4 more articles in the media than Quantum Biopharma. MarketBeat recorded 5 mentions for Nutriband and 1 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.00 beat Nutriband's score of -0.10 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nutriband	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.7% of Nutriband shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 52.2% of Nutriband shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nutriband has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Quantum Biopharma has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. Nutriband's return on equity of -109.07% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-109.07%	-95.54%
Quantum Biopharma	N/A	-582.23%	-184.20%

Summary

Nutriband beats Quantum Biopharma on 9 of the 15 factors compared between the two stocks.

How does Quantum Biopharma compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Milestone Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Milestone Pharmaceuticals' return on equity of -288.33% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Quantum Biopharma	N/A	-582.23%	-184.20%

Quantum Biopharma has lower revenue, but higher earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	65.04	-$63.06M	-$0.69	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

In the previous week, Quantum Biopharma had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 1 mentions for Quantum Biopharma and 0 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled Quantum Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Milestone Pharmaceuticals	Neutral
Quantum Biopharma	Neutral

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Milestone Pharmaceuticals presently has a consensus price target of $6.40, indicating a potential upside of 690.42%. Quantum Biopharma has a consensus price target of $8.00, indicating a potential upside of 132.56%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Milestone Pharmaceuticals beats Quantum Biopharma on 10 of the 14 factors compared between the two stocks.

How does Quantum Biopharma compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ImmuCell has a net margin of 2.57% compared to Quantum Biopharma's net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Quantum Biopharma	N/A	-582.23%	-184.20%

ImmuCell has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.20	-$1.04M	$0.08	121.88
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

Quantum Biopharma has a consensus target price of $8.00, indicating a potential upside of 132.56%. Given Quantum Biopharma's higher possible upside, analysts clearly believe Quantum Biopharma is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ImmuCell has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

In the previous week, Quantum Biopharma had 1 more articles in the media than ImmuCell. MarketBeat recorded 1 mentions for Quantum Biopharma and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.00 equaled Quantum Biopharma'saverage media sentiment score.

Company	Overall Sentiment
ImmuCell	Neutral
Quantum Biopharma	Neutral

Summary

ImmuCell beats Quantum Biopharma on 9 of the 13 factors compared between the two stocks.

How does Quantum Biopharma compare to Cognition Therapeutics?

Quantum Biopharma (NASDAQ:QNTM) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

Cognition Therapeutics' return on equity of -50.17% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Cognition Therapeutics	N/A	-50.17%	-40.22%

Quantum Biopharma has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Quantum Biopharma currently has a consensus target price of $8.00, indicating a potential upside of 132.56%. Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 260.32%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cognition Therapeutics had 2 more articles in the media than Quantum Biopharma. MarketBeat recorded 3 mentions for Cognition Therapeutics and 1 mentions for Quantum Biopharma. Cognition Therapeutics' average media sentiment score of 0.66 beat Quantum Biopharma's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cognition Therapeutics beats Quantum Biopharma on 12 of the 13 factors compared between the two stocks.

Get Quantum Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNTM vs. The Competition

Export

Metric	Quantum Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$26.45M	$12.12B	$7.17B	$13.38B
Dividend Yield	N/A	2.65%	2.53%	17.32%
P/E Ratio	-0.60	799.72	274.64	26.20
Price / Sales	N/A	755.20	608.57	90.53
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	2.44	10.68	11.26	6.40
Net Income	-$26.17M	$2.83B	$3.49B	$381.07M
7 Day Performance	-17.42%	-2.20%	-1.68%	-0.66%
1 Month Performance	0.93%	-6.55%	-5.97%	-4.51%
1 Year Performance	-82.28%	-4.52%	8.11%	1.82%

Quantum Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNTM Quantum Biopharma	1.8908 of 5 stars	$3.27 -4.9%	$8.00 +144.6%	-81.4%	$27.82M	N/A	N/A	7
PYPD PolyPid	2.9502 of 5 stars	$5.29 -0.4%	$11.33 +114.2%	+48.3%	$101.33M	N/A	N/A	75
NTRB Nutriband	0.6478 of 5 stars	$8.25 +0.2%	N/A	-2.0%	$100.29M	$1.62M	N/A	3
MIST Milestone Pharmaceuticals	1.8344 of 5 stars	$0.82 +3.1%	$6.40 +680.5%	-61.6%	$99.03M	$2.34M	N/A	38
ICCC ImmuCell	0.6258 of 5 stars	$9.94 +0.6%	N/A	+54.5%	$89.73M	$27.64M	124.27	73	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNTM) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quantum Biopharma (QNTM) Competitors

QNTM vs. PYPD, NTRB, MIST, ICCC, and CGTX

How does Quantum Biopharma compare to PolyPid?

Summary

How does Quantum Biopharma compare to Nutriband?

Summary

How does Quantum Biopharma compare to Milestone Pharmaceuticals?

Summary

How does Quantum Biopharma compare to ImmuCell?

Summary

How does Quantum Biopharma compare to Cognition Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quantum Biopharma (QNTM) Competitors

QNTM vs. PYPD, NTRB, MIST, ICCC, and CGTX

How does Quantum Biopharma compare to PolyPid?

Do analysts rate PYPD or QNTM?

Which has better earnings and valuation, PYPD or QNTM?

Does the media prefer PYPD or QNTM?

Do institutionals & insiders hold more shares of PYPD or QNTM?

Is PYPD or QNTM more profitable?

Which has more volatility & risk, PYPD or QNTM?

Summary

How does Quantum Biopharma compare to Nutriband?

Do analysts prefer NTRB or QNTM?

Which has higher earnings and valuation, NTRB or QNTM?

Does the media refer more to NTRB or QNTM?

Do insiders and institutionals hold more shares of NTRB or QNTM?

Which has more volatility & risk, NTRB or QNTM?

Is NTRB or QNTM more profitable?

Summary

How does Quantum Biopharma compare to Milestone Pharmaceuticals?

Which has more volatility and risk, MIST or QNTM?

Is MIST or QNTM more profitable?

Which has better valuation and earnings, MIST or QNTM?

Does the media refer more to MIST or QNTM?

Do insiders & institutionals believe in MIST or QNTM?

Do analysts prefer MIST or QNTM?

Summary

How does Quantum Biopharma compare to ImmuCell?

Do insiders and institutionals believe in ICCC or QNTM?

Is ICCC or QNTM more profitable?

Which has better earnings & valuation, ICCC or QNTM?

Do analysts rate ICCC or QNTM?

Which has more risk & volatility, ICCC or QNTM?

Does the media prefer ICCC or QNTM?

Summary

How does Quantum Biopharma compare to Cognition Therapeutics?

Do insiders and institutionals hold more shares of QNTM or CGTX?

Which has better valuation and earnings, QNTM or CGTX?

Is QNTM or CGTX more profitable?

Which has more volatility & risk, QNTM or CGTX?

Do analysts prefer QNTM or CGTX?

Does the media favor QNTM or CGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools